Launch Of Affordable Pressurized Metered Dose Inhaler For Asthma And COPD Treatment Industry Trends Gaining Momentum in the Global Metered Dose Inhaler Devices Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Metered Dose Inhaler Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the market size for metered dose inhaler devices has seen robust growth. It is predicted to rise from $15.46 billion in 2024 to $16.23 billion in 2025, registering a compound annual growth rate (CAGR) of 5.0%. The historical growth is due to a variety of factors such as a rise in diabetes cases, heightened demand for metered dose inhaler devices, an increase in the amount of metered dose inhaler devices available, and a growing prevalence of COPD.

Metered Dose Inhaler Devices Market Size Forecast: What's the Projected Valuation by 2029?
The market for metered dosed inhaler devices is anticipated to experience robust growth in the upcoming years. It is forecasted to climb to $20.03 billion by 2029, with a compound annual growth rate (CAGR) of 5.4%. The projected growth in this period can be largely ascribed to an increase in chronic obstructive pulmonary diseases, an amplified occurrence of asthma, a rise in infectious diseases, surging diabetes rates, and an escalation in respiratory diseases. Key trends that will mark this forecast period consist of breakthroughs in technology, pioneering treatments, regulatory endorsements, the introduction of novel inhalers, and the use of digital marketing tools.

View the full report here:
https://www.thebusinessresearchcompany.com/report/metered-dose-inhaler-devices-global-market-report

What Are the Drivers Transforming the Metered Dose Inhaler Devices Market?
The escalation in the occurrence of chronic obstructive pulmonary diseases is set to fuel the expansion of the metered dose inhaler devices market. Chronic obstructive pulmonary disease (COPD) is a progressive disease affecting the lungs, manifested by an obstruction of airflow, usually instigated by enduring exposure to irritants like cigarette smoke, resulting in symptoms such as breathlessness, coughing, and wheezing. The rise in chronic obstructive pulmonary disease (COPD) is propelled by variables like tobacco consumption, air contamination, aging demographics, and procrastinated diagnosis or treatment. Metered dose inhaler (MDI) devices play a crucial role in the management of chronic obstructive pulmonary disease (COPD) by administering drugs directly to the lungs, providing immediate relief and enhancing airflow. For example, the National Institutes of Health, a government agency based in the US, forecasted in December 2023 that COPD cases are projected to ascend from 532 million in 2030 to a total of 592 million by 2050. Hence, the rising prevalence of chronic obstructive pulmonary diseases is boosting the growth of the metered dose inhaler devices market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20878&type=smp

What Are the Key Trends Driving Metered Dose Inhaler Devices Market Growth?
Key players in the metered dose inhaler devices market are concentrating on creating technologically advanced offerings to bolster drug delivery efficiency and heighten patient adherence. This includes the development of pressurized metered-dose inhalers (pMDIs) which facilitate the delivery of an accurate dosage of medication in aerosol format via pressurized propellant. As an illustration, Lupin Limited, an Indian pharmaceutical business, rolled out Luforbec 100/6 in Germany in July 2023-a pMDI designed for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD). The product constitutes a blend of beclometasone (100 μg) and formoterol (6 μg), translating to a potent solution for patients necessitating combination therapy. Significantly, Luforbec has been priced approximately 47% below the fixed reference price, thus increasing its affordability. Given that asthma is found in nearly 5% of adults in Germany, the introduction of Luforbec reflects Lupin's sustained dedication towards catering to crucial healthcare demands and elevating patient results in respiratory care.

Which Segments in the Metered Dose Inhaler Devices Market Offer the Most Profit Potential?
The metered dose inhaler devices market covered in this report is segmented -

1) By Type: Desktop Metered Dose Inhaler Devices, Portable Metered Dose Inhaler Devices, Other Types
2) By Distribution Channel: Online, Offline
3) By Application: Asthma, Chronic Obstructive Pulmonary Disease, Other Applications
4) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:
1) By Desktop Metered Dose Inhaler Devices: Standard desktop MDI devices, High-performance desktop MDI devices, Smart desktop MDI devices
2) By Portable Metered Dose Inhaler Devices: Conventional portable MDI devices, Advanced portable MDI devices, Smart portable MDI devices
3) By Other Types: Nebulizer-Based MDI devices, Dry powder inhaler (DPI) combined devices, Soft mist inhaler (SMI) devices, Other specialized MDI devices

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=20878&type=smp

Which Firms Dominate the Metered Dose Inhaler Devices Market by Market Share and Revenue in 2025?
Major companies operating in the metered dose inhaler devices market are Pfizer Inc., Merck & Co. Inc., AstraZeneca PLC, GlaxoSmithKline plc, 3M Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Berry Global Inc., AptarGroup Inc., Philips Healthcare, Chiesi Farmaceutici S.p.A., Cipla Limited, Gerresheimer AG, Zydus Lifesciences Limited, Mylan N.V., Nemera, Beximco Pharmaceuticals Limited, Cohero Health Inc., Bespak Europe Ltd., Trudell Medical International, Iconovo AB

Which Regions Offer the Highest Growth Potential in the Metered Dose Inhaler Devices Market?
North America was the largest region in the metered dose inhaler devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metered dose inhaler devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20878

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.